This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: GILD to Buy IMMU, SGEN Collaborates With Merck & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Vaxart Gets FDA Nod for Phase I Study on Coronavirus Vaccine
by Zacks Equity Research
Vaxart's (VXRT) investigational new drug application for oral coronavirus vaccine candidate gets a clearance from the FDA. The company will begin a phase I study later this month.
Do Options Traders Know Something About Vaxart (VXRT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.
Coronavirus Vaccine Efforts Key to Vaxart (VXRT) Q2 Earnings
by Zacks Equity Research
Vaxart (VXRT) has been working on developing a coronavirus vaccine. Increased clinical activity is expected to have increased expenses.
Emergent (EBS) Beats Q2 Earnings Estimates, Ups '20 Guidance
by Zacks Equity Research
Emergent's (EBS) second-quarter earnings beat estimates on robust product sales. Concurrently, it increases its annual guidance.
Vaxart (VXRT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Vaxart (VXRT) has been actively engaged in developing a coronavirus vaccine. Investors are likely to focus on progress of vaccine program on the Q2 earnings call.
COVID-19 Vaccine Push Brings Hope: Stock & ETF Beneficiaries
by Sanghamitra Saha
There are at least a hundred candidates in the COVID-19 vaccine race globally. However, few companies like Moderna, Pfizer and AstraZeneca are showing considerable hope.
The Zacks Analyst Blog Highlights: AstraZeneca, Pfizer, Moderna, Vaxart and Novovax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AstraZeneca, Pfizer, Moderna, Vaxart and Novovax
3 Small Biotechs in Focus on Promising Coronavirus Vaccine Data
by Zacks Equity Research
Pfizer (PFE) and AstraZeneca (AZN) announce promising data from early-stage coronavirus vaccine studies. Here we discuss three leading biotechs with potential to recshare price gains.
Vaxart's Soars YTD on Robust Coronavirus Vaccine Progress
by Zacks Equity Research
Vaxart's (VXRT) oral coronavirus vaccine candidate is chosen by Operation Warp Speed for a vaccine study. Last month, the company picked its lead COVID-19 vaccine candidate.
Vaxart (VXRT) Catches Eye: Stock Jumps 7.9%
by Zacks Equity Research
Vaxart (VXRT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Implied Volatility Surging for Vaxart (VXRT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.
Biotech Stock Roundup: GILD Prices Remdesivir, VXRT Rises, ICPT Plunges & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline developments.
Vaxart's Oral Coronavirus Vaccine Candidate Gets Chosen by OWS
by Zacks Equity Research
Vaxart's (VXRT) oral COVID-19 vaccine candidate is picked for a non-human primate challenge study as part of the Operation Warp Speed initiative to rapidly develop a vaccine against SARS-CoV-2.
Company News for Jun 29, 2020
by Zacks Equity Research
Companies in the news are: GPS, CLGX, AXSM, VXRT
Vaxart Gets New CEO, Focuses on Coronavirus Vaccine Program
by Zacks Equity Research
Vaxart (VXRT) management names Andrei Floroiu as its next chief executive officer with immediate effect. Stock appreciates on this news.
Emergent (EBS) Down on Unfavorable Patent Ruling on Narcan
by Zacks Equity Research
Emergent's (EBS) stock falls after a district court rules against the patent litigation on its Narcan nasal spray product. The court ruled in favor of Teva Pharmaceuticals, the defendants.
Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up
by Sanghamitra Saha
Efforts in formulating a coronavirus vaccine are heating up. These stocks and ETFs look to be the largest beneficiaries.
Emergent (EBS) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Emergent's (EBS) earnings and revenues surpass estimates in the first quarter of 2020. The company reaffirms its guidance for the ongoing year.
Vaxart (VXRT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
During Vaxart's (VXRT) upcoming Q1 earnings call, investor focus will be on the company's progress with its oral vaccine candidates against SARS CoV-2.
Vaxart Up on Pre-Clinical Data on Coronavirus Vaccine Candidates
by Zacks Equity Research
Vaxart's (VXRT) several COVID-19 vaccine candidates generate immune responses in pre-clinical studies. Stock rises.
Biotech Stock Roundup: ALXN, MRNA Up on Coronavirus Treatment Updates, & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Company News for Apr 22, 2020
by Zacks Equity Research
Companies In The News Are: SYF, VXRT, PAVM, WAFD
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Moderna, Sanofi, Vaxart and Eli Lilly
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Moderna, Sanofi, Vaxart and Eli Lilly
Buy 5 Top Medical Stocks on Coronavirus Drug Trial Results
by Nalak Das
The whole world has pinned hopes on pharmaceutical and biotech companies to create drugs and vaccine to help combat COVID-19.